Technology | June 06, 2011

AngioDynamics Launches VenaCure 1470nm Laser for Treatment of Varicose Veins

June 6, 2011 – AngioDynamics has expanded its VenaCure EVLT System product offering with the global launch of the new VenaCure 1470nm laser to treat varicose veins with greater energy efficiency.

“Our VenaCure 1470 endovenous laser has shown to be highly efficient in the treatment of varicose veins, as it utilizes a lower power output compared with other lasers to achieve effective vein closure,” said Tom Kupec, Vice President of Marketing for AngioDynamics. “The new laser is complemented by the benefits of our NeverTouch gold-tip fiber, designed to result in improved procedure parameters for patients and physicians.”

The VenaCure 1470nm laser’s light energy is precisely delivered through the NeverTouch gold-tip fiber, and is more readily absorbed by the water in the blood and endothelial lining than is the case with other wavelengths. The NeverTouch fiber’s jacketed tip has been engineered to maximize clinical efficacy and minimize post-operative pain and bruising. It has a lower power density and is designed to virtually eliminate the risk of direct contact between the laser fiber and vein wall.

“Our research group found excellent vein closure rates, minimal postoperative discomfort and bruising, and a clear reduction in symptom severity over the follow-up period. By allowing for the more efficient transfer of energy to the vein, this new long wavelength laser translated into improved clinical outcomes as compared to short wavelength lasers we have studied,” said Jose I. Almeida, M.D., FACS, managing partner, Vascular Device Partners, LLC.

The VenaCure 1470nm lasers are manufactured in AngioDynamics’ Cambridge, U.K., facility, which has been established as a center of excellence and reliability. It has received the CE mark, and a 510 (k) approval.

For more information: www.VenaCure-EVLT.com, www.angiodynamics.com

Related Content

Illustration showing the self-expanding deployment of the Boston Scientific Vici venous stent in the iliofemoral vein.

Illustration showing the self-expanding deployment of the Vici stent in the iliofemoral vein. 

Technology | Venous Therapies | May 06, 2019
May 6, 2019 — The U.S Food and Drug Administration (FDA) has cleared the Boston Scientific Vici Venous Stent System f
The U.S. Food and Drug Administration (FDA) recently cleared Bard Peripheral Vascular's Venovo Venous Stent System intended to treat narrowed iliofemoral veins.
Technology | Venous Therapies | April 03, 2019
April 3, 2019 — The U.S.
News | Venous Therapies | August 08, 2018
Boston Scientific Corp. announced it has signed an agreement to acquire Veniti Inc., which has developed and...
A patient case study showing a venous ulcer formation 18 months following thermal ablation varicose vein treatment in the GSV. The patient was treated with Varithena polidocanol endovenous microfoam chemical-ablation. Images show baseline prior to treatment (right), followed by one, four and six weeks after treatment. The treatment is also called sclerotherapy.

A patient case study showing a venous ulcer formation 18 months following thermal ablation varicose vein treatment in the GSV. The patient was treated with Varithena polidocanol endovenous microfoam chemical-ablation. Images show baseline prior to treatment (right), followed by one, four and six weeks after treatment.

Feature | Venous Therapies | April 30, 2018 | Tif Siragusa, M.D.
The introduction of thermal ablation revolutionized the treatment of varicose veins, yet recurrence remains a stubbor
Medtronic Launches IDE Study of Abre Venous Self-Expanding Stent
News | Venous Therapies | January 26, 2018
Medtronic plc announced the initiation of its investigational device exemption (IDE) study for the Abre venous self-...
Videos | Venous Therapies | June 27, 2017
This video, provided by Ekos, demonstrates the EkoSonic endovascular System thrombolytic system to treat deep vein th
New Data Demonstrate Clinical and Quality-of-Life Benefits for VenaSeal Closure System in Venous Reflux Disease Patients
News | Venous Therapies | May 05, 2017
Medtronic plc recently announced three-year outcomes from the VeClose U.S. pivotal clinical trial and one-year data...
News | Venous Therapies | April 26, 2017
A new Varicose Vein Registry has begun producing useful outcomes information, as reported in the May edition of the...
News | Venous Therapies | September 12, 2016
Veniti Inc. has closed on $25 million in Series D equity financing from Boston Scientific Corp. The funds will allow...
Overlay Init